7-Chloro-1-methyl-3-(naphthalen-2-ylmethyl)-3,4-dihydro-1,4-benzodiazepine-2,5-dione

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯二氮卓类
• 英文名称: 7-Chloro-1-methyl-3-(naphthalen-2-ylmethyl)-3,4-dihydro-1,4-benzodiazepine-2,5-dione
• 化学式: C₂₁H₁₇ClN₂O₂
• 分子量: 364.831
• InChiKey: WMZLCGFJUCZICO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  26
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  49.4
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  DL-3-(2-萘基)丙氨酸 、 5-氯-N-甲基靛红酸酐 在 溶剂黄146 作用下， 反应 7.0h， 生成 7-Chloro-1-methyl-3-(naphthalen-2-ylmethyl)-3,4-dihydro-1,4-benzodiazepine-2,5-dione
  参考文献：
  名称：

  鉴定具有细胞毒性的T细胞选择性1,4-苯并二氮杂2,5-二酮。

  摘要：

  已经合成了1,4-苯并二氮杂-2,5-二酮（BZDs）家族，并针对转化的B细胞和T细胞进行了淋巴毒性检测。C3位置上的一个较大的芳族基团对于细胞毒性至关重要。当C3部分包含一个富含电子的杂环时，所得BZD具有亚微摩尔浓度，并且对T细胞具有选择性。细胞死亡与细胞凋亡一致，而不是由于线粒体F（o）F1-ATPase的抑制而引起的，线粒体F（o）F1-ATPase是最近报道的具有细胞毒性的1,4-苯并二氮杂the的分子靶标。集体地，这些研究开始表征一些新型T细胞选择性淋巴毒性药物家族的活性所需的结构要素。

  DOI：

  10.1016/j.bmcl.2006.01.113

文献信息

• NOVEL 1,4-BENZODIAZEPINE-2,5-DIONES WITH THERAPEUTIC PROPERTIES
  申请人：The Regents of the University of Michigan

  公开号：EP1948191B1

  公开（公告）日：2013-01-16
• Therapeutic applications of pro-apoptotic benzodiazepines
  申请人：Glick D. Gary

  公开号：US20070036854A1

  公开（公告）日：2007-02-15

  Benzodiazepine compounds, and methods for using those compounds are provided. Some of the benzodiazepine compounds include 1,4-benzodiazepine-2-one and 1,4-benzodiazepine-2,5-dione compounds of the following structures: wherein R 1 , R 2 , R 3 and R 4 are as defined. The invention also includes enantiomers, pharmaceutically acceptable salts, prodrugs or derivatives of the benzodiazepine compounds. Any one or more of these benzodiazepine compounds can be used to treat a variety of dysregulatory disorders related to cellular death. Such disorders include autoimmune disorders, inflammatory conditions, hyperproliferative conditions, viral infections, and atherosclerosis. In addition, the above compounds can be used to prepare medicaments to treat the above-described dysregulatory disorders. The benzodiazepines can also be used in drug screening assays and other diagnostic methods.
• Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties
  申请人：Glick D. Gary

  公开号：US20070111994A1

  公开（公告）日：2007-05-17

  The present invention relates to novel chemical compounds, methods for their discovery, and their therapeutic use. In particular, the present invention provides novel 1,4-benzodiazepine-2,5-dione compounds, and methods of using novel 1,4-benzodiazepine-2,5-dione compounds as therapeutic agents to treat a number of conditions associated with the faulty regulation of the processes of programmed cell death, autoimmunity, inflammation, hyperproliferation, and the like.
• Methods and compositions for treating diseases and conditions associated with mitochondrial function
  申请人：Glick Gary D.

  公开号：US20090275099A1

  公开（公告）日：2009-11-05

  The present invention relates to chemical compounds, methods for their discovery, and their therapeutic use. In particular, the present invention provides compounds as therapeutic agents to treat a number of conditions associated with the faulty regulation of the processes of programmed cell death, autoimmunity, inflammation, hyperproliferation, mitochondrial F 1 F 0 ATP hydrolase associated disorders, and the like.
• THERAPEUTIC APPLICATIONS OF PRO-APOPTOTIC BENZODIAZEPINES
  申请人：Glick Gary D.

  公开号：US20140038947A1

  公开（公告）日：2014-02-06

  Benzodiazepine compounds, and methods for using those compounds are provided. Some of the benzodiazepine compounds include 1,4-benzodiazepine-2-one and 1,4-benzodiazepine-2,5-dione compounds of structures: wherein R 1 , R 2 , R 3 and R 4 are as defined. The invention also includes enantiomers, pharmaceutically acceptable salts, prodrugs or derivatives of the benzodiazepine compounds. Any one or more of these benzodiazepine compounds can be used to treat a variety of dysregulatory disorders related to cellular death. Such disorders include autoimmune disorders, inflammatory conditions, hyperproliferative conditions, viral infections, and atherosclerosis. In addition, the above compounds can be used to prepare medicaments to treat the above-described dysregulatory disorders. The benzodiazepines can also be used in drugs screening assays and other diagnostic methods.